Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Albireo is a clinical-stage biopharmaceutical company focused on the development a...
Albireo is a clinical-stage biopharmaceutical c...
Esembly Inc. sells organic & sustainable cloth diapers.
Esembly Inc. sells organic & sustainable cloth ...
For over 20 years Streamline Health has provided solutions that address the fundam...
For over 20 years Streamline Health has provide...
Inogenâs mission to improve the quality of life of supplemental oxygen users beg...
Inogenâs mission to improve the quality of li...
Trinity Biotech specializes in the development, manufacture and marketing of diagn...
Trinity Biotech specializes in the development,...
Eclipes Diagnostics develops CANABINOX, a handheld testing device that can accurat...
Eclipes Diagnostics develops CANABINOX, a handh...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our ...
Since our foundation in Dublin, Ireland in 1990...
Join the National Investor Network and get the latest information with your interests in mind.